FDA approves perioperative bladder cancer treatment
FDA approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each with Padcev (enfortumab vedotin-ejfv), as treatment before and after surgery for adults with muscle-invasive bladder cancer (MIBC).
MRK•
